--FILE--un lavoratore cinese mostra di dosi di vaccino ad un impianto di Shenzhen Kangtai Prodotti Biologici Co. Ltd., noto anche come BioKangtai, in Shenzhen cit
--FILE--A Chinese worker shows doses of vaccine at a plant of Shenzhen Kangtai Biological Products Co. Ltd., also known as BioKangtai, in Shenzhen city, south China's Guangdong province, 27 February 2014. Shenzhen Kangtai Biological Products announced on July 25 that the company's controlling shareholder Du Weimin plans to buy at least CNY60 million (USD9 million) worth of shares in the company through Shenzhen Stock Exchange¯s securities trading system (including but not limited to centralized bidding and block trading) within 12 months. Kangtai Biological Products stocks [SHE:300601] opened then went to limit down today but followed by a CNY1.6 billion (USD260 million) influx of funds invested in the company¯s shares in the first 10 minutes of the opening session, narrowing the decline to about 6 percent. By today¯s afternoon close, however, its shares still fell by 8.74 percent to CNY47.60 per share, with a volume of CNY2.6 billion and a market value of CNY30.2 billion. *** Local Caption ***
